NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Busà Photography / Getty Images Many people believe that being wealthy means having a nice house, a late-model car, and a summer cottage, but the kind of money possessed by the wealthiest 1% of ...

The pharma world , esp the big boys dont play clean .. IMM have now done their job and its now down to a big boys to finish it or delay it .. The conference would have been the place to close the deal ...

IMM-1-104 combined with mGnP shows promising efficacy and tolerability in first-line pancreatic cancer, with a 43% ORR and 86% DCR among seven patients. IMM-1-104 demonstrated target lesion shrinkage ...

(1) when that person’s mother was unlawfully present in the United States and the person’s father was not a United States citizen or lawful permanent resident at the time of said person’s ...

Copyright 2025 The Associated Press. All Rights Reserved. Toronto Raptors forward Scottie Barnes (4) and Golden State Warriors forward Gui Santos (15) vie for control ...

“We are thrilled to report two more responses in our Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer,” said Ben Zeskind, Ph.D., CEO of ...

Immuneering Corp (NASDAQ:IMRX), a biopharmaceutical company focusing on drug development with a market capitalization of $63.34 million, has announced promising interim data from its ongoing Phase 2a ...